{"id":21092,"date":"2025-01-09T21:20:15","date_gmt":"2025-01-09T13:20:15","guid":{"rendered":"https:\/\/flcube.com\/?p=21092"},"modified":"2025-01-09T21:21:40","modified_gmt":"2025-01-09T13:21:40","slug":"medtronics-harmony-tpv-system-gains-ce-mark-for-minimally-invasive-heart-valve-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21092","title":{"rendered":"Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment"},"content":{"rendered":"\n

US-Irish firm Medtronic (NYSE: MDT<\/a>) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA’s approval of the product in 2021.<\/p>\n\n\n\n

Product Overview and Clinical Trials<\/strong>
The Harmony TPV System has been implanted in over 2,200 patients, demonstrating its ease of implantation, conformability to the anatomy, and strong clinical and hemodynamic outcomes. Clinical trials have shown that the system provides significant benefits for congenital heart disease patients, with positive results observed up to three years post-implantation.<\/p>\n\n\n\n

Significance of the CE Mark<\/strong>
The CE marking for the Harmony TPV System is a testament to Medtronic’s commitment to providing innovative and minimally invasive solutions for complex cardiac conditions. This approval will enable the company to offer this advanced treatment option to a broader patient population in Europe, enhancing the standard of care for those with congenital heart disease.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System…<\/p>\n","protected":false},"author":1,"featured_media":21093,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[233,1031,15],"class_list":["post-21092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-medtronic","tag-nyse-mdt","tag-product-approvals"],"yoast_head":"\nMedtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA's approval of the product in 2021.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21092\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment\" \/>\n<meta property=\"og:description\" content=\"US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA's approval of the product in 2021.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21092\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T13:20:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T13:21:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"412\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment\",\"datePublished\":\"2025-01-09T13:20:15+00:00\",\"dateModified\":\"2025-01-09T13:21:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092\"},\"wordCount\":209,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0912.png\",\"keywords\":[\"Medtronic\",\"NYSE: MDT\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21092#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21092\",\"name\":\"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0912.png\",\"datePublished\":\"2025-01-09T13:20:15+00:00\",\"dateModified\":\"2025-01-09T13:21:40+00:00\",\"description\":\"US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA's approval of the product in 2021.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21092\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0912.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0912.png\",\"width\":1080,\"height\":412,\"caption\":\"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21092#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment - Insight, China's Pharmaceutical Industry","description":"US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA's approval of the product in 2021.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21092","og_locale":"en_US","og_type":"article","og_title":"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment","og_description":"US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA's approval of the product in 2021.","og_url":"https:\/\/flcube.com\/?p=21092","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T13:20:15+00:00","article_modified_time":"2025-01-09T13:21:40+00:00","og_image":[{"width":1080,"height":412,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21092#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21092"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment","datePublished":"2025-01-09T13:20:15+00:00","dateModified":"2025-01-09T13:21:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21092"},"wordCount":209,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21092#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png","keywords":["Medtronic","NYSE: MDT","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21092#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21092","url":"https:\/\/flcube.com\/?p=21092","name":"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21092#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21092#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png","datePublished":"2025-01-09T13:20:15+00:00","dateModified":"2025-01-09T13:21:40+00:00","description":"US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) and severe pulmonary valve regurgitation (PR). This endorsement follows the FDA's approval of the product in 2021.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21092#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21092"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21092#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png","width":1080,"height":412,"caption":"Medtronic's Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21092#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0912.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21092"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21092\/revisions"}],"predecessor-version":[{"id":21094,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21092\/revisions\/21094"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21093"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}